CD30.CAR-EBVST cells

BIOLOGICAL2 trials

Sponsors

Baylor College of Medicine

Conditions

Classical Hodgkin LymphomaExtranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Phase 1

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Active, not recruitingNCT04288726

Baylor College of MedicineClassical Hodgkin Lymphoma, Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Start: 2020-09-16End: 2037-06-01Updated: 2026-08-26

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

WithdrawnNCT04952584

Baylor College of MedicineClassical Hodgkin Lymphoma, Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Start: 2024-03-31End: 2040-06-30Updated: 2023-09-07

Related Papers

Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma

Blood Advances2024-04-193 citations

OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL)

Hematological Oncology2023-06-0111 citations

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy

Journal for ImmunoTherapy of Cancer2023-04-0111 citations

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Blood2022-11-1522 citations

240 Humanized CD30 chimeric antigen receptor T cells with a novel 4–1BB derived spacer have improved activity and safety against CD30-positive lymphomas

Regular and Young Investigator Award Abstracts2022-11-01

CD45RA expressing lymphocytes inhibit the outgrowth of Epstein-Barr Virus Specific T-cells from Patients with EBV+ Lymphoma

The Journal of Immunology2022-05-01

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

Blood2020-11-056 citations